CN1060533A - 诊断和识别胸痛早期发作的诊断盒 - Google Patents
诊断和识别胸痛早期发作的诊断盒 Download PDFInfo
- Publication number
- CN1060533A CN1060533A CN91109633A CN91109633A CN1060533A CN 1060533 A CN1060533 A CN 1060533A CN 91109633 A CN91109633 A CN 91109633A CN 91109633 A CN91109633 A CN 91109633A CN 1060533 A CN1060533 A CN 1060533A
- Authority
- CN
- China
- Prior art keywords
- antibody
- diagnosis
- test box
- reagent
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003745 diagnosis Methods 0.000 title claims abstract description 42
- 206010008479 Chest Pain Diseases 0.000 title description 2
- 238000012360 testing method Methods 0.000 claims abstract description 43
- 210000002966 serum Anatomy 0.000 claims abstract description 38
- 206010061216 Infarction Diseases 0.000 claims abstract description 34
- 230000007574 infarction Effects 0.000 claims abstract description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 29
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 18
- 230000000747 cardiac effect Effects 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 210000004165 myocardium Anatomy 0.000 claims abstract description 11
- 230000000295 complement effect Effects 0.000 claims abstract description 8
- 102000004420 Creatine Kinase Human genes 0.000 claims description 21
- 108010042126 Creatine kinase Proteins 0.000 claims description 21
- 239000003550 marker Substances 0.000 claims description 16
- 102000004987 Troponin T Human genes 0.000 claims description 11
- 108090001108 Troponin T Proteins 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 108060008487 Myosin Proteins 0.000 claims description 8
- 102000003505 Myosin Human genes 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 210000000518 sarcolemma Anatomy 0.000 claims description 4
- -1 TnC Proteins 0.000 claims description 3
- 102000004903 Troponin Human genes 0.000 claims description 3
- 108090001027 Troponin Proteins 0.000 claims description 3
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 claims description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 claims description 2
- 102000013394 Troponin I Human genes 0.000 claims description 2
- 108010065729 Troponin I Proteins 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 description 15
- 210000002027 skeletal muscle Anatomy 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000005937 Tropomyosin Human genes 0.000 description 7
- 108010030743 Tropomyosin Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- 208000013875 Heart injury Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 101000573526 Homo sapiens Membrane protein MLC1 Proteins 0.000 description 4
- 101000635885 Homo sapiens Myosin light chain 1/3, skeletal muscle isoform Proteins 0.000 description 4
- 208000029549 Muscle injury Diseases 0.000 description 4
- 102100030739 Myosin light chain 4 Human genes 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- 102000036675 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003683 cardiac damage Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000011229 interlayer Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 108010065781 myosin light chain 2 Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
- 101150095787 ldh2 gene Proteins 0.000 description 1
- 101150100271 ldhb gene Proteins 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003157 protein complementation Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/81—Tube, bottle, or dipstick
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明公布的诊断用诊验盒是为了评价在患者
胸痛发作初期究竟胸痛是否源于心脏,以及将变异性
心绞痛和心脏梗塞区别开。该试验盒是由一个为接
受和保留患者血液和血清样品的接受器和悬浮于载
体上的至少三个单克隆和多克隆抗体。每个抗体与
一不同的蛋白相互补,该蛋白是在心肌梗塞早期从心
肌中释放的,每个抗体有相应的试剂,后者对每个抗
体与相应蛋白反应时作出独立的应答。对试剂作出
应答的综合揭示了患者诊断时的状况。
Description
本发明涉及新的药板形式的一步诊断试验法,用来作为一种精确、简便、迅速和便携的诊断方法,以判断患者的胸痛是否源于心脏,并在患者胸痛的早期发作时区别出是易变性心绞痛还是心肌梗塞(“MI”)。特别是本药板用酶免疫试验夹层干化学形式同时测定了心脏受损伤时或损伤后血清或血浆中出现的三种不同的物质或标示物的水平。在本发明的优选的实施例中,这三个标示物是肌酸激酶(CK),肌红蛋白和肌浆球蛋白轻链(MLC)。
心肌梗塞的紧急诊断取决于内科长征的敏锐性和对患者症状的评估,例如胸痛或胸压迫感,显可能放射到下到臂部,上到颈部,疲劳,要死的感觉,呼吸短促,苍白,皮肤冷湿,外周发绀或数丝状脉。
大多数北美的胸痛患者在发作6小时内报告给医生或急诊室。因此,在MI早期阶段进行有效的诊断试验是至关重要的。
有数种心脏检查方法用于诊察MI。这些检查方法包括ECG,SGOT/AST,LDH,CK-MB免疫试验和NA乳液肌红蛋白颗粒增强试验。然而还没有用单一酶心脏检查法能使急诊室医生确定胸痛是来自心脏或不是来自心脏的原因。而且只有在确证了是心肌梗塞后,才开始溶解血栓的治疗。这种治疗开始得越早,患者完全康复的可能性就越大或至少使心脏损伤只在最低程度。因此,内科先生确定这种疼痛是心脏性的还是非心脏性的,是至关重要的。
心电图(ECG)可用来诊察MI。然而只有心脏受到严重损伤时心电图才能诊断出。ECG的诊断特异性对开始阶段的胸痛只有51%。因此,ECG不适宜用于MI的早期诊察。
血清谷氨酸草酰乙酸转氨酶/天门冬氨酸转氨酶(SGOT/AST)在心肌中有高浓度,是占优势的酶。血清试验测定SGOT水平可用来诊断心肌梗塞。然而,SGOT只在胸痛发作后的大约8-10小时后才开始升高,在24-36小时内达到峰值,5-7天后恢复正常。患者在胸痛早期和紧急处置时SGOT在诊断心肌梗塞上是没有特殊帮助的。SGOT对心肌也不是特异的。已发现许多包含骨骼肌的组织,如肝和肾脏,由于肌肉注射,休克,肝脏病和肝充血时,SGOT被释放,因此这在诊察特异的心脏组织损害上价值不大。
乳酸脱氢酶(LDH)在许多组织中浓度很高,这些组织包括心脏,骨骼肌和肝脏,检查血清中LDH的存在的试验被用来诊断心肌梗塞。在五种普通的同型中心脏主要含有LDH1和LDH2。胸痛发作24-36小时后LDH水平开始增高,48-72小时后达峰值,4-8天后回复正常。因此,患者在胸痛早期不能用LDH作为MI的指标。此外对心脏损伤LDH不是特异的,在肺栓塞、溶血,肝充血,肾脏病和骨骼肌损伤时LDH会出现。这种特异性的缺乏降低了LDH作为诊断手段的应用。
肌酸激酶(CK)是肌肉组织中的一种酶。CK催化肌酸和三磷酸腺苷(ATP)转变为磷酸肌酸和二磷酸腺苷(ADP)的反应。CK的数个同功酶中的CK-MB在心脏组织中。CK-MB对诊查心肌梗塞是个灵敏的标示物,因为它在心肌组织受损伤时释放出。故而CK-MB存在于受损伤患者的血清之中,图1说明了患者血清中CK浓度与时间的关系(文献Lee T.H.等(1986)Ann.Intern.Med.105,221-233)。
CK-MB免疫试验是诊断心肌梗塞的标准检查法。美国专利No.4900662公布了CK-MB的应用方法,题目是“CK-MM心肌梗塞免疫试验”。
Shah在USP4900662中公布了在患者心肌梗塞后测定血清中初始增高的CK-MM-a(CK-MM的异型)浓度和同时测定CK-MM-a和CK-MM-b的方法。用这个方法可提供一种对梗塞的时间的精确估计。该方法包括测定血清中CK-MM-a和CK-MM-b的总浓度和CK-MM-a的浓度,以确定心肌梗塞急性期的时间。公布的试剂包括有CK-MM-a的多克隆抗体和单克隆抗体,这类抗体并不明显地与CK-MB,CK-MM-b或CK-MM-c结合,有抗CK-MM-b抗体,它不会明显地与CK-MB,CK-MM-a或CK-MM-c结合,有抗CK-MM-a+b抗体,它可与CK-MM-a和CK-MM-b结合,但不能明显地与CK-MB或CK-MM-c结合,还包括这些抗体的标记的衍生物,固着这些抗体的不溶性的支持物,以及含有一种或多种这些试剂的药盒。酶标记的和放射性标记的CK试剂特别有用。
单独使用CK-MB作为诊断标示物是有些困难的。首先,心肌梗塞发作后只有在6-8小时后CK-MB的血清浓度才增高,而且12小时后才达峰,造成早期紧急诊断和治疗的困难。
第二,CK-MB试验必须在实验室中由训练有素的技术员进行。在非城区不易进行这样的试验,结果也不能迅速得的解析,致使延误了诊断,因此,就患者等候诊断的住院费而言,增加了保证机构的负担。
第三,CK-MB处于正常骨骼肌组织中,因此,使该试验结果对心脏不够特异,诊断不够肯定。
肌红蛋白是位于骨骼肌或心肌细胞膜的邻近的另一种蛋白质。细胞膜的通透性一旦变得异常,例如心脏缺血时的一个可逆状态,肌红蛋白立即被细胞排出。在胸痛发作1.5小时内,在血清中即可检查出肌红蛋白。医学研究团体认为,心肌坏死释放肌红蛋白,因此它是心肌损伤的一个有用的早期标示物。图2说明了血清中肌红蛋白浓度与时间的关系(文献:Grenadier E.等(1981)Am.Heart J.105,408-416;Seguin J.等(1988)J.Thorac Car-diovasc Surg.95,294-297)。
胸痛发作后2-3小时内若未检查出血清肌红蛋白水平增高,则在确定疼痛原因时可排除急性心肌梗塞。
“NA乳液肌红蛋白颗粒增强测定”是检查肌红蛋白的市场有售的药盒。这种检查试验是基于人体体液中存在的抗原与共价链偶联于聚苯乙烯颗粒上的抗肌红蛋白抗体间的反应。把样品、N肌红蛋白试剂、一种除掉非特异性反应的溶液和N反应缓冲液自动地移液到比包池内,温孵12分钟后用浊度法测定光散射,同标准曲线计算肌红蛋白的浓度。
放射免疫试验也可测定肌红蛋白,但还有一种无酶联结的免疫吸附剂检验(ELISA)装置也能采用。
单用肌红蛋白指标诊断心肌梗塞具有困难性。肌红蛋白不能指出心肌操作的特殊类型,例如心肌梗塞,在像休克、肾脏病,横纹肌溶解和肌病等各样不同的情况下,也可有肌红蛋白存在。此外,血清和血浆中肌红蛋白的浓度通常随年令与性别而变,健康的正常人浓度变化范围很宽,血清浓度高达90ug/l时通常认为是健康人群的高限。因此,对此人可能是正常水平的浓度,对其它人就可能是严重问题的指征,做诊断时要比预料的准确度略差。
肌浆球蛋白轻链(MLC)是肌浆球蛋白肌原纤维的整体部分,但其功能尚不清楚,MLC存在于快、慢、心房和心室肌肉之中,已知MLC对心脏缺血非常敏感。心肌坏死后血清中迅速出现MLC,提高的浓度可维持长达10天,图3说明了患者血清中MLC浓度与时间的关系(文献:Wang J.等(1989)Clin.Chimica Acta 181,325-336;Jackowski G.,Symmes J.等(1989)Circulation Suppl 11,80,355)。
MLC确定溶血栓治疗是否成功也有预后的价值。MLC的浓度越高,预后越差,也表明梗塞越严重。在数天内浓度下降表示患者趋于康复,而高高低低或平台样曲线表明有梗塞趋势需做手术。
MLC主要有两种,称作MLC1和MLC2,存在于心肌细胞胞浆的可溶性库中,也可完整的存在于肌浆球蛋白肌原纤维中,心室肌细胞中的MLC2,或许还有MLC1与慢骨骼肌细胞中的同型是一样的。心脏疼痛患者的MLC1水平提高80-85%。MLC1对易变性心绞痛和冠心病是非常灵敏的指征。
其它类的心脏标示物,如低分子量的心肌蛋白(LMWCP)可作为心脏的标示物。这类标示物的实例包括收缩器官的成分,即肌钙蛋白,肌钙蛋白-T,肌钙蛋白-I和肌钙蛋白C,线粒体酶,如三糖P异构酶,易自心脏释放出的低分子量多肽,以及局部缺血发作后早期就释放的肌纤维膜蛋白或蛋白片数,特别是分子量为15kd的肌纤维膜蛋白和100kd的复合糖蛋白对心脏是特异的。
该心脏肌钙蛋白-I同型可抑制心肌收缩间静止期的肌纤蛋白和肌浆球蛋白分子间的相互作用。在MI后4-6小时内患者血清内出现肌钙蛋白I,并且这种增高的水平持续7-8天。图4说明了肌钙蛋白-I浓度与时间的关系。(文献:Cummins B.,Auckland M.L.和Cummins P.(1987)Am.Heart J.113,1333-1344)。肌钙蛋白-I对心脏是特异的标示物,在诊查是心肌损伤还是骨骼肌损伤时,比其它标示物更灵敏。
肌钙蛋白-T是薄丝状的肌钙蛋白-原肌球蛋白的复合物的构成成份,联结原肌球蛋白骨架和肌钙蛋白-I肌钙蛋白C复合物,肌钙蛋白-T是个碱性蛋白质,在心脏和快、慢骨骼肌中具有同型。MI发作后3小时内血清中即出现并且增高的水平至少持续10天。图5说明了肌钙蛋白-T的浓度与时间的关系(文献:Katus H.A.等(1989)J.Mol.Cell Cardiol.21,1349-1453)。肌钙蛋白-T的释放按双相的样式,对心脏是特异的,并且对MI非常灵敏。
肌浆球蛋白重链(MHC)和原肌球蛋白是分子量较大的蛋白质,也可作为心脏的标示物。MHC是肌肉主要收缩蛋白的构成部分。在心肌细胞坏死和随后的膜的不可逆损伤后,MHC的片断就会由心室中释放到血清中。虽然在心肌细胞坏死后,MHC片断不会迅速出现于血清中,但在MI后MHC增高的浓度至少持续10天,并且在MI后第4天可观测到MHC的峰值。图6说明了MHC浓度与时间的关系(文献:Leger J.O.C.等(1985)Eur.J.of Clin.Invet.15,422-429;Sequin J.R.等(1989)J.Thorac.Cardiovase Surga,397-401)。MHC释放曲线下面积与心肌细胞损伤程度有非常好的相关性。然而在MI的急性期MHC水平对临床价值不大。
原肌球蛋白是由两个多肽形成的二聚体,是肌肉收缩的调节系统的构成部分。在心肌梗塞发作后大约7-8小时,可检测出血清中的原肌球蛋白。如同CK-MB一样,它对心肌梗塞非常敏感。图7说明了MLC浓度与时间的关系(文献:CumminsP.等(1981)Clin.Sci.60,251-259)然而,骨骼肌损伤时,原肌球蛋白的浓度也会增高,因此它不是心脏特异性的。
现用的心肌梗塞的标准诊断方法都有局限性。在胸痛发作后,没有一种方法能立即提供非常灵敏、特异迅速和简便的诊断检查,例如在急救车或医生办公室中。
本发明是在胸痛发作的早期测定患者血液或血清中因心脏损伤存在的至少三种不同的标示物,并将它们综合在一起,以提供一种心肌梗塞诊断的改良方法,用于易变性心绞痛或MI的早期诊断。
以前的诊断方法的缺陷可用一种准确、快速和便携的一步式诊断板加以克服,以用于急诊处置中检测心脏受损伤的患者血清中存在的至少三种标示物。试验结果将确定患者是患了易变性心绞痛还是心肌梗塞。MI的早期诊断仍能在早期开始进行溶血栓治疗。因而心脏损伤会降到最低水平,从而增加了患者的生存机会。即使在疼痛发作数天之后,本诊断板的试验结果也可以区分易变性心绞痛和心肌梗塞。该诊断板是利用酶免疫试验夹层干化学型板。用这种板进行系列的短暂的测定,可为内科医生提供关于心脏损伤的程度和溶血栓处置的预后的信息。本发明的优越实施例中,这三个标示物是肌酸激酶(CK),肌红蛋白和肌原纤维轻链(MLC)。
本发明的一个内容是提供了一种诊断用试验盒,用以在患者胸痛的早期发作时检查出心肌梗塞。该试验盒包括一个可容纳和保留患者血液或血清样品的贮存部和一个与血样进行反应的检测装置。该检测装置的组成是,至少有三种悬浮于载体上的单克隆或多克隆抗体,每一种抗体与早期心肌梗塞时自心肌释放的不同的蛋白质相互补,以及独立地与应答互补的蛋白进行反应的各个抗体的相应的试剂。与试剂反应的效果的综合,应提示诊断时患者心脏的状况。
本发明的实施例用图加以说明。
图1是血清中CK浓度与时间的关系作图;
图2是血清中肌红蛋白浓度与时间的作图;
图3是血清中MLC浓度与时间的作图;
图4是血清中肌钙蛋白-I浓度与时间的作图;
图5是血清中肌钙蛋白-T浓度与时间的作图;
图6是血清中MHC浓度与时间的作图;
图7是血清中原肌球蛋白浓度与时间的作图;
图8是优选的实施例的平面观;
图9是图8实例的分解透视图;
图10是图18的实例中膜的偏斜图;
图11是膜的第二个实例的偏斜图。
本发总的用图8加以说明。本发明的优选实例是一块如1所示的板。
所用板的样式是已知的,可以买到,该板的形状与现用的综合妊娠试验板相似,可以买到,商品名为BIOSIGN。
板是由聚丙烯片构成,分前板10和后板12。前板10有一显示窗口14,每一个心脏标示物对应一个口,还有一个样品口16,如图9所示。在前板10下面有一块暴露的干化学膜18,后者用适当的方法粘连在前板10的背面。后板12有个绕其一周的边20,以与前板10严格扣合。这样,把膜18封在前后板之间。
前板和后板的扣合如所述的那样,但还有许多其它的适宜的联结方法,对熟悉此类技艺的人来说这是明显的。
前板10也能提供一块区域13,上面可写上患者的姓名和身份,也可用来书写测定结果。
关于图10,膜18是单克隆和多克隆抗体的载体。在优选的实例中,将血液或血清按箭头方向由一端流向另一端。端点22与样品窗口16对在一起。固定不动的抗体24层压在或连到抗体一酶结合物26上,后者针对抗原的不同的表位,而不会被抗体24识别。抗体24与肌浆球蛋白互补。同样,抗体28层压在相应的试剂30上。抗体28互补于CK-MB。同样,抗体32层压在试剂34上。抗体32与肌浆球蛋白轻链互补。抗体36与正常血液或血清中存在的任何蛋白互补。抗体36层压在试剂38上。
单克隆和多克隆抗体可用常规方法,由制备多克隆抗体的哺乳动物中制取。
在优选实例中用标记的试剂,该抗体试剂标记到或用化学方法键合于可被观测或测定的特定的部位,以便对血清或血液中存在的抗体或干化学膜上抗体的存在加以验证或定量。可以与本发明的用作诊断工具的抗体相结合的配基和基团,包括有元素、化合物或生物物质,它们所具有的物理或化学特性可用来区别与它们链合的抗体与其它的抗体。
每个心脏标示物至少需要两种类型为单/多或兔/多,山羊/多的抗体。这些抗体对它们的心脏免疫原进行亲合性纯化,再用交叉吸附法对非相关种属的免疫原进一步纯化,以除去非特异性免疫球蛋白。
使用时诊断师例如内科医生、急救车护理或护士将三滴或低于100ul的患者血清或血液加到样品窗口16中。样品会由于毛细作用沿膜18移动并相继与抗体和试剂对(24和26,28和30,32和34以及36和38)相接触。
若血样中有特异的心脏标示物,则与固定在膜上的抗体相结合。相应的试剂也会与之反应并可由试剂颜色的改变而看出。这种颜色的变化与血样中标示物的浓度成比例。这样,若在一定时间间隔用此试验盒检查,可以确定标示物的浓度增高或降低,作为诊断工具。在3-5分钟内就能完成检查结果。
在优选的实例中,测定的样品中的各个心脏标示物均会出现一个蓝色色带。色带的深浅强度可用反射计定量,颜色的强度与特定的标示物的浓度相关。反射计可包括有微处理机,在板上被检测的每个心脏标示物的定量结果以浓度大小和患者的姓名或身份一起打印出来。
用三滴或低于100ul的血清或血浆测定时,标示物的浓度为0.5ng/ml-25ng/ml最为敏感,每次测定和数次测定之间的精确度,变异系数低于15%。
在测定中所用的心脏标示物将取决于那些标示物的性质。优选实例用的板有肌红蛋白、MLC和CK-MB,如图8所示。
肌红蛋白从心肌细胞中释放非常早,它不是心脏所特异的,对心肌梗塞和坏死有非常高的灵敏性,在无坏死情况下的缺氧损伤是不会释放出的。MLC是心脏特异性的,用以区别心脏性的和非心脏性的疼痛,它的释放也快但不像肌红蛋白那样快。CK-MB可将心绞痛和心肌梗塞区分开,但只有在胸痛发作6小时后才能检测出,因此不能单独用于急诊诊断。
如果所用的心脏的三个标示物是CK-MB,肌红蛋白和MLC,参考图1,2,和3,其结果对诊断可用如下的解析。
若诊断板显示阳性的MLC和阴性的肌红蛋白和CK-MB,则提示患者的胸痛是心脏性的,原因是易变性心绞痛。
若肌红蛋白和MLC是阳性结果,CK-MB是阴性的,提示为早期心肌梗塞,可开始干预治疗。
若三种都是阳性结果,提示为心肌梗塞。
若MLC和CK-MB是阳性,肌红蛋白为阴性,则提示为心肌梗塞。
若肌红蛋白和CK-MB为阳性而MLC为阴性,则患者可能有骨骼肌损伤(假阳性)或是心肌梗塞中期。
在这种情况下该试验不能区分假阳性和“小”的心肌梗塞,因为MLC释放曲线在数个间隔中稍许下沉,病人可能有轻度心内膜下梗塞,并且在“下沉”时刻测定。当梗塞很小时,这种“下沉”几乎达到正常水平,因而测定的患者MLC为阴性。阳性诊断要依赖于CK-MB的存在。
心肌梗塞大的患者,MLC的“下沉”并不大到与正常水平一样,因此MLC仍可检测出。
其它实例的试验板是用同样的格式,抗体有不同的组合,这样来评估心脏的不同的标出物。
为了保证在患者胸痛的早期能用这种试验板检测出心肌组织的损伤,必须用至少一种相应于在心脏损伤的初期有大量的存在的标示物的抗体,即例如CK,肌浆球蛋白轻链或肌球蛋白。具有CK、肌浆球蛋白轻链或肌球蛋白特征和性质的低分子量心脏蛋白也可用在药盒中,
适宜的蛋白和酶可选自:肌钙蛋白,肌钙蛋白-I,肌钙蛋白C,肌钙蛋白-T和肌纤维膜蛋白,三糖磷酸异构酶或者具有肌酸激酶、肌浆蛋白轻链或肌球蛋白特性和性质的各种重分子量心脏蛋白。
其它蛋白质例如原肌球蛋白和肌浆球蛋白重链也可加到诊断盒中。如果患者前来求诊是在胸痛发作许多小时后而且患者的MI处于较晚阶段,则该试验盒可检测MI。
第二个实例是膜18上可有一层被捕获的抗体124及相应的试剂126。同样为了检测其它各个标示物,要有成对的相应的抗体和试剂,即128和130,132和134以及对照组对136和138。使用时,把血样滴到每对试药上,用上述相同的方式读出结果。
干化学膜118可用吸收性物质120支持。吸收性物质120可增加血清向膜内的透入力。
另一个试验盒的实例是用血样品管,这种管通常用来从患者身上抽取血样,管的内壁作为单克隆和多克隆抗体及试剂的载体。从患者身上抽取血样后,使用者只要振摇样品管,抗体就会与血液反应。如果血液中存在心脏蛋白,就会发生如前所述的颜色变化。
本发明书虽然对优选实例作了阐述和说明,但不要认为本发明只局限于这些持定的实例。对本技术熟悉的会作许多变换和改进。本发明的界定可参见权利要求。
Claims (18)
1、在患者胸痛发作早期诊察心肌梗塞的一种诊断试验盒,它包括有一个可容纳和保留患者血液或血清样品的贮存部和一个与血样进行反应的检测装置。该检测装置的组成是,至少有三种悬浮于载体上的单克隆或多克隆抗体,每一种抗体与心肌梗塞早期自心肌释放的各种蛋白之一相互补,以及独自地应与互补的蛋白进行反应的各个抗体的相应的试剂,并把试剂反应的结果综合起来以提示作诊断时患者的心脏状况。
2、按照权利要求1的一种诊断试验盒,其特征是,该单克隆和多克隆抗体与下列蛋白质或酶的至少三种相互补:肌酸激酶,肌红蛋白,肌浆蛋白轻链,肌钙蛋白,肌钙蛋白-Ⅰ,肌钙蛋白C,肌钙蛋白-T和肌纤维膜蛋白,三糖磷酸异构酶或者具有肌酸激酶、肌红蛋白或肌浆球蛋白轻链、特征和性质的各种低分子量心脏蛋白,肌球蛋白或者具有肌酸激酶、肌红蛋白或肌浆球层白轻链特征和性质的各种高分子量心脏蛋白,其中至少有两种要选自肌酸激酶、肌红蛋白、肌浆球蛋白轻链和肌钙蛋白-T。
3、按照权利要求2的一种诊断用试验盒,其特征是,该单克隆和多克隆抗体是一种固定不动的抗体,层压在其相应的试剂上,该试剂是抗体-酶结合物,针对不同的表位而不会被抗体识别。
4、按照权利要求3的一种诊断用试验盒,其特征是,当每一种抗体与其相应的蛋白反应时的应答,是该试剂改变颜色。
5、按照权利要求4的一种诊断用试验盒,其特征是,该颜色的改变与样品中互补的蛋白质浓度成比例。
6、按照权利要求5的一种诊断用试验盒,其特征是,该接受器是有一个用来接受样品的样品窗口和一个用来展现试剂的展示窗口的前板,一个后板和封闭装置,用以确保前板和后板把载体封在当中,从而形成整体。
7、按照权利要求6的一种诊断用试验盒,其特征是,该载体是个干化学膜。
8、按照权利要求7的一种诊断用试验盒,其特征是,所说的膜是被吸收性物质所支持,以增强样品向检验部位的渗入。
9、按照权利要求8的一种诊断用试验盒,其特征是,该膜延伸到加样窗口和显示窗口处,抗体及其相应的试剂在空间上的关系是从加样窗口进到显示窗口。
10、按照权利要求9的一种诊断用试验盒,其特征是,该前板用来显示鉴定蛋白抗体反应的定位。
11、按照权利要求10的一种诊断用试验盒,其特征是,前板还连接一反射计,以定量样品中蛋白的浓度。
12、按照权利要求11的一种诊断用试验盒,其特征是,该检测手段包括一个对照抗体,它与血清中正常存在的蛋白质相互补,和一个相应的试剂,该试剂对于相互补的蛋白进行反应的对照抗体可作出应答,这样的应答结果提示该试验是有效的。
13、按照权利要求12的一种诊断用试验盒,其特征是,该对照抗体和相应的蛋白在载体上的位置要远离加样窗口以指示该试验真实地完成了。
14、按照权利要求5的一种诊断用试验盒,其特征是,该接受器是一种封闭式的清洁的容器,该载体是容器的边。
15、按照权利要求13或14的一种诊断用试验盒,其特征是,单克隆和多克隆抗体与肌酸激酶和肌红蛋白互补。
16、抗照权利要求15的一种诊断用试验盒,其特征是,这些抗体与肌酸激酶,肌红蛋白和肌钙蛋白-T互补。
17、按照权利要求15和一种诊断用试验,其特征是,这些抗体与肌酸激酶、肌红蛋白和肌钙蛋白-T互补。
18、按照权利要求15和一种诊断用试验,其特征是,在用少于100nl样品时,该试验对标示物浓度为0.5ng/ml-25ng/ml是灵敏的。每次测定和数次测定的准确度,变异系数低于15%。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,027,434 | 1990-10-12 | ||
CA002027434A CA2027434C (en) | 1990-10-12 | 1990-10-12 | Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1060533A true CN1060533A (zh) | 1992-04-22 |
CN1036155C CN1036155C (zh) | 1997-10-15 |
Family
ID=4146144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN91109633A Expired - Fee Related CN1036155C (zh) | 1990-10-12 | 1991-10-11 | 诊断和识别胸痛早期发作的诊断盒 |
Country Status (15)
Country | Link |
---|---|
US (1) | US5290678A (zh) |
JP (1) | JP2628421B2 (zh) |
KR (1) | KR0167564B1 (zh) |
CN (1) | CN1036155C (zh) |
AR (1) | AR247634A1 (zh) |
BE (1) | BE1004994A5 (zh) |
BR (1) | BR9104431A (zh) |
CA (1) | CA2027434C (zh) |
DE (1) | DE4122886C2 (zh) |
ES (1) | ES2070658B1 (zh) |
FR (1) | FR2667944B1 (zh) |
GB (1) | GB2248688B (zh) |
IT (1) | IT1251682B (zh) |
MX (1) | MX9101550A (zh) |
NZ (1) | NZ239938A (zh) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604105B1 (en) * | 1990-10-12 | 1999-08-24 | Spectral Diagnostics Inc | Method and device for diagnosingand distinguishing chest pain in early onset thereof |
US5710008B1 (en) * | 1990-10-12 | 1999-09-07 | Spectral Diagnostics Inc | Method and device for diagnosing and distinguishing chest pain in early onset thereof |
WO1994003807A1 (en) * | 1992-08-03 | 1994-02-17 | Gec-Marconi Limited | Separation method |
US5807752A (en) * | 1992-09-11 | 1998-09-15 | Boehringer Mannheim Corporation | Assay using an unblocked solid phase with immobilized analyte binding partner |
DE4243648A1 (de) * | 1992-12-23 | 1994-07-07 | Boehringer Mannheim Gmbh | Verfahren zur Bestimmung von Herzmuskelnekrosen mittels Antikörper gegen das N-terminale Troponin I-Peptid |
FR2701954B1 (fr) * | 1993-02-23 | 1995-07-07 | Pasteur Sanofi Diagnostics | Composition stabilisée de troponine pour immunoessais et procédé de stabilisation de troponine pour immunoessais. |
ATE184400T1 (de) * | 1993-05-17 | 1999-09-15 | Fortron Bioscience Inc | Assay für troponin i aus dem herzmuskel |
CA2130280C (en) * | 1993-08-24 | 1999-08-31 | Lilian Lee | Method for purification of cardiac troponin i |
US5658801A (en) * | 1994-05-03 | 1997-08-19 | Spectral Diagnostics Inc. | Medical test kit |
US5573957A (en) * | 1994-09-28 | 1996-11-12 | Spectral Diagnostics, Inc. | Monoclonal antibody to human cardiac myoglobin |
US5702905A (en) * | 1994-09-28 | 1997-12-30 | Spectral Diagnostics | Monoclonal antibody to human ventricular myosin light chains |
AU3483395A (en) * | 1994-09-28 | 1996-04-19 | Spectral Diagnostics Inc. | A monoclonal antibody to human cardiac troponin i |
DE69633780T3 (de) | 1995-04-18 | 2011-05-05 | Biosite Incorporated, San Diego | Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays |
US6627404B1 (en) * | 1995-04-18 | 2003-09-30 | Biosite, Inc. | Methods for improving the recovery of troponin I and T in membranes, filters and vessels |
US5795725A (en) * | 1995-04-18 | 1998-08-18 | Biosite Diagnostics Incorporated | Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays |
US6991907B1 (en) | 1995-04-18 | 2006-01-31 | Biosite, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
FR2734267B1 (fr) * | 1995-05-16 | 1997-08-01 | Pasteur Sanofi Diagnostics | Composition stabilisee de troponine pour immunoessais et procede de preparation d'une telle composition stabilisee |
WO1997006725A1 (en) * | 1995-08-17 | 1997-02-27 | Duke University | Method of assessing reperfusion after thrombolytic therapy |
AU6764196A (en) * | 1995-08-31 | 1997-03-19 | First Medical, Inc. | Methods and antibodies for detecting creatine kinase |
US6611634B2 (en) | 1996-03-19 | 2003-08-26 | University Of Utah Research Foundation | Lens and associatable flow cell |
JPH09304393A (ja) * | 1996-05-15 | 1997-11-28 | Ind Technol Res Inst | 急性心筋梗塞診断キット |
US5690103A (en) * | 1996-06-20 | 1997-11-25 | Groth; Torgny Lars | Detection/exclusion of acute myocardial infarction using neural network analysis of measurements of biochemical markers |
US6156521A (en) * | 1997-12-19 | 2000-12-05 | Biosite Diagnostics, Inc. | Methods for the recovery and measurement of troponin complexes |
US5834210A (en) * | 1997-05-23 | 1998-11-10 | Spectral Diagnostics, Inc. | Stable troponin subunits and complexes |
US6248869B1 (en) | 1997-05-29 | 2001-06-19 | Medical Analysis Systems, Inc. | Troponin I forms and use of the same |
DE69842017D1 (de) | 1997-06-10 | 2011-01-05 | Lpath Inc | Verfahren zum frühzeitigen nachweis herzerkrankungen |
US5961470A (en) * | 1997-07-09 | 1999-10-05 | Wagner; David A. | Breath test for assessing hepatic function |
US7384751B1 (en) * | 1997-07-16 | 2008-06-10 | Queen's University At Kingston | Methods of diagnosing muscle damage |
US6222619B1 (en) | 1997-09-18 | 2001-04-24 | University Of Utah Research Foundation | Diagnostic device and method |
US6475785B1 (en) | 1997-12-18 | 2002-11-05 | Spectral Diagnostics, Inc. | Single-chain polypeptides comprising troponin I N-terminal fragments and troponin C |
US6077676A (en) * | 1997-12-18 | 2000-06-20 | Spectral Diagnostics, Inc. | Single-chain polypeptides comprising troponin I and troponin C |
US6410341B1 (en) | 1998-08-06 | 2002-06-25 | Spectral Diagnostics, Inc. | Analytical test device and method for use in medical diagnoses |
US6171870B1 (en) | 1998-08-06 | 2001-01-09 | Spectral Diagnostics, Inc. | Analytical test device and method for use in medical diagnoses |
US6214629B1 (en) | 1998-08-06 | 2001-04-10 | Spectral Diagnostics, Inc. | Analytical test device and method for use in medical diagnoses |
US6432126B1 (en) | 1998-09-30 | 2002-08-13 | C.R. Bard, Inc. | Flexible vascular inducing implants |
US7070937B1 (en) | 1998-10-02 | 2006-07-04 | Ischemia Technologies, Inc. | Marker useful for detection and measurement of free radical damage and method |
US20030215359A1 (en) * | 1998-10-02 | 2003-11-20 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
US7449338B2 (en) * | 1998-10-02 | 2008-11-11 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
US7282369B2 (en) * | 1998-10-02 | 2007-10-16 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
US20050142613A1 (en) * | 1998-10-02 | 2005-06-30 | David Bar-Or | Test for the rapid evaluation of ischemic states and kits |
US6475743B1 (en) | 1998-10-02 | 2002-11-05 | Ischemia Technologies, Inc. | Marker useful for detection and measurement of free radical damage and method |
GB9827411D0 (en) | 1998-12-11 | 1999-02-03 | Axis Biochemicals Asa | Dipstick assay |
US6780606B1 (en) * | 1999-02-26 | 2004-08-24 | Synx Pharma, Inc. | Method for diagnosing and distinguishing stroke and diagnostic devices for use therein |
CA2263063C (en) * | 1999-02-26 | 2004-08-10 | Skye Pharmatech Incorporated | Method for diagnosing and distinguishing stroke and diagnostic devices for use therein |
US7618782B1 (en) | 1999-10-18 | 2009-11-17 | Queen's University At Kingston | Methods of diagnosing muscle damage |
US7078486B2 (en) * | 1999-12-10 | 2006-07-18 | Spectral Diagnostics, Inc. | Single-chain polypeptides comprising troponin I and troponin C |
GB9929140D0 (en) * | 1999-12-10 | 2000-02-02 | Univ Geneve | Diagnostic assay for stroke |
AU5828201A (en) * | 2000-03-10 | 2001-09-17 | Univ Geneve | Diagnostic assay for transmissible spongiform encephalopathies |
US7204847B1 (en) | 2000-07-28 | 2007-04-17 | C. R. Bard, Inc. | Implant anchor systems |
US6858590B2 (en) * | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
ATE375804T1 (de) | 2000-08-17 | 2007-11-15 | Tripep Ab | Ribavirin-enthaltende vakzine |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US6680059B2 (en) * | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
WO2002016947A2 (en) * | 2000-08-21 | 2002-02-28 | Queen's University At Kingston | Methods and kits for separation and detection of proteins in biological samples |
US6673562B2 (en) | 2000-08-24 | 2004-01-06 | Spectral Diagnostics, Inc. | Differential immunoassay |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20030199000A1 (en) * | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
US20040176914A1 (en) * | 2001-04-13 | 2004-09-09 | Biosite Incorporated | Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
DE60235416D1 (de) * | 2001-05-04 | 2010-04-01 | Biosite Inc | Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen |
JP2005522669A (ja) * | 2001-08-20 | 2005-07-28 | バイオサイト インコーポレイテッド | 卒中および脳損傷の診断マーカーおよびその使用方法 |
US7608406B2 (en) * | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US6461828B1 (en) | 2001-09-04 | 2002-10-08 | Syn X Pharma | Conjunctive analysis of biological marker expression for diagnosing organ failure |
US20030054414A1 (en) * | 2001-09-17 | 2003-03-20 | George Jackowski | Diagnosis and treatment of early pre-type-1 diabetes utilizing glial fibrillary acidic protein |
AU2002364894A1 (en) * | 2001-11-09 | 2003-06-30 | Neurogenetics, Inc. | Single nucleotide polymorphisms and mutations on alpha-2-macroglobulin |
US20040067512A1 (en) * | 2001-11-09 | 2004-04-08 | Neurogenetics, Inc. | Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin |
GB0216191D0 (en) * | 2002-07-11 | 2002-08-21 | Univ Leicester | Plasma urotensin in human heart failure |
US20050014198A1 (en) * | 2002-07-11 | 2005-01-20 | Leong Ng | Assays and kits for detecting and monitoring heart disease |
GB0224425D0 (en) * | 2002-10-21 | 2002-11-27 | Univ Leicester | Method for prediction of cardiac disease |
WO2006032126A1 (en) * | 2004-09-24 | 2006-03-30 | Syn X Pharma, Inc. | Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins |
JP4727997B2 (ja) * | 2005-01-12 | 2011-07-20 | シスメックス株式会社 | イムノクロマトグラフィー用キット |
CA2618429A1 (en) | 2005-05-25 | 2007-03-22 | Tripep Ab | A hepatitis c virus non-structural ns3/4a fusion gene |
JP4891317B2 (ja) * | 2005-06-28 | 2012-03-07 | ズィービーエックス・コーポレーション | 膜アレイ及び分析用装置 |
US8586006B2 (en) * | 2006-08-09 | 2013-11-19 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
EP2185195A2 (en) * | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
WO2009130588A2 (en) * | 2008-04-22 | 2009-10-29 | Tripep Ab | Immunogen platform |
WO2010129302A1 (en) * | 2009-04-28 | 2010-11-11 | Innovative Laboratory Technologies, Inc. | Lateral-flow immuno-chromatographic assay devices |
WO2010129845A1 (en) * | 2009-05-07 | 2010-11-11 | University Of Cincinnati | Methods of preventing ischemic injury using peripheral nociceptive stimulation |
US20110306148A1 (en) | 2010-06-14 | 2011-12-15 | Siemens Healthcare Diagnostics Inc. | Composition for use as an assay reagent |
EP2596347B1 (en) | 2010-07-22 | 2017-09-06 | Hach Company | Alkalinity analysis using a lab-on-a-chip |
WO2012060845A1 (en) * | 2010-11-05 | 2012-05-10 | University Of Cincinnati | Methods of preventing ischemic injury using peripheral nociceptive stimulation |
US20140370502A1 (en) | 2011-09-08 | 2014-12-18 | Nexus Dx, Inc. | Multilevel analyte assay |
US9180449B2 (en) | 2012-06-12 | 2015-11-10 | Hach Company | Mobile water analysis |
USD768872S1 (en) | 2012-12-12 | 2016-10-11 | Hach Company | Cuvette for a water analysis instrument |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5411231A (en) * | 1977-06-27 | 1979-01-27 | Daiichi Radioisotope Lab | Production of purified antiimyoglobin antibody and quantitative analysis of myoglobin |
US4353982A (en) * | 1980-04-10 | 1982-10-12 | Hoffmann-La Roche Inc. | Immunochemical assay for creatine kinase-MB isoenzyme |
US4624916A (en) * | 1984-04-06 | 1986-11-25 | International Immunoassay Laboratories, Inc. | Process and composition for the rapid quantitation of small levels of creative kinase-MB isoenzyme |
US4999285A (en) * | 1984-11-15 | 1991-03-12 | Syntex (U.S.A.) Inc. | Chromatographic cassette |
IE59210B1 (en) * | 1985-11-14 | 1994-01-26 | Univ Washington | Creatine kinase mb determination method |
JPS62151192A (ja) * | 1985-12-24 | 1987-07-06 | Denka Seiken Co Ltd | ヒト心筋ミオシン軽鎖に対する単一クロ−ン抗体 |
DE3640318A1 (de) * | 1986-11-26 | 1988-06-09 | Boehringer Mannheim Gmbh | Verfahren und testtraeger zur bestimmung eines analyten |
DE3707746A1 (de) * | 1987-03-11 | 1988-09-22 | Boehringer Mannheim Gmbh | Spezifische antikoerper gegen herzmuskelmyosin-leichtketten, ihre herstellung und verwendung in einem reagenz zur bestimmung von herzmuskelmyosin-leichtketten |
CA1303983C (en) * | 1987-03-27 | 1992-06-23 | Robert W. Rosenstein | Solid phase assay |
US4857453A (en) * | 1987-04-07 | 1989-08-15 | Syntex (U.S.A.) Inc. | Immunoassay device |
CA1340557C (en) * | 1987-04-09 | 1999-05-25 | Christine A. Vitkauskas | Ckmb assay and monoclonal antibodies for use in same |
CA1313616C (en) * | 1987-06-01 | 1993-02-16 | Robert B. Sargeant | Lateral flow, non-bibulous membrane protocols |
US4900662A (en) * | 1987-07-21 | 1990-02-13 | International Immunoassay Laboratories, Inc. | CK-MM myocardial infarction immunoassay |
JPS6461664A (en) * | 1987-08-18 | 1989-03-08 | Maikurobaiorojikaru Res Corp | Solid phase enzyme immunological inspection system and processing therefor |
JPH01233298A (ja) * | 1988-03-11 | 1989-09-19 | Boehringer Mannheim Gmbh | 抗体、その製造法、hmlcを測定するための試薬、ならびにモノクローナル抗体 |
DE3814370A1 (de) * | 1988-04-28 | 1989-11-09 | Boehringer Mannheim Gmbh | Testtraeger fuer die analyse einer probenfluessigkeit, verfahren zur durchfuehrung einer solchen analyse und herstellungsverfahren |
JPH01302162A (ja) * | 1988-05-31 | 1989-12-06 | Tosoh Corp | ヒトミオグロビンの測定方法 |
US5087556A (en) * | 1989-05-17 | 1992-02-11 | Actimed Laboratories, Inc. | Method for quantitative analysis of body fluid constituents |
GB8916718D0 (en) * | 1989-07-21 | 1989-09-06 | Vioclone Biolog Inc | Use of creatine kinase and its isozyme ck-mb and human ventricular myosin light chain 1 in the diagnosis of heart failure |
-
1990
- 1990-10-12 CA CA002027434A patent/CA2027434C/en not_active Expired - Lifetime
-
1991
- 1991-05-03 US US07/695,381 patent/US5290678A/en not_active Expired - Lifetime
- 1991-06-04 GB GB9111965A patent/GB2248688B/en not_active Expired - Lifetime
- 1991-07-11 DE DE4122886A patent/DE4122886C2/de not_active Expired - Lifetime
- 1991-08-01 BE BE9100710A patent/BE1004994A5/fr not_active IP Right Cessation
- 1991-09-25 NZ NZ239938A patent/NZ239938A/en not_active IP Right Cessation
- 1991-09-30 ES ES09102146A patent/ES2070658B1/es not_active Expired - Fee Related
- 1991-10-03 AR AR91320837A patent/AR247634A1/es active
- 1991-10-09 JP JP3262301A patent/JP2628421B2/ja not_active Expired - Lifetime
- 1991-10-10 IT ITMI912687A patent/IT1251682B/it active IP Right Grant
- 1991-10-11 CN CN91109633A patent/CN1036155C/zh not_active Expired - Fee Related
- 1991-10-11 MX MX9101550A patent/MX9101550A/es not_active IP Right Cessation
- 1991-10-11 FR FR9112584A patent/FR2667944B1/fr not_active Expired - Lifetime
- 1991-10-11 BR BR919104431A patent/BR9104431A/pt not_active IP Right Cessation
- 1991-10-12 KR KR1019910017994A patent/KR0167564B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GB2248688B (en) | 1995-07-12 |
AU8475791A (en) | 1992-04-16 |
AR247634A1 (es) | 1995-01-31 |
CA2027434C (en) | 1999-01-05 |
GB2248688A (en) | 1992-04-15 |
AU654672B2 (en) | 1994-11-17 |
BR9104431A (pt) | 1992-06-09 |
NZ239938A (en) | 1994-03-25 |
GB9111965D0 (en) | 1991-07-24 |
IT1251682B (it) | 1995-05-19 |
DE4122886C2 (de) | 2000-03-02 |
CA2027434A1 (en) | 1992-04-13 |
ITMI912687A1 (it) | 1993-04-10 |
ES2070658A1 (es) | 1995-06-01 |
ITMI912687A0 (it) | 1991-10-10 |
US5290678A (en) | 1994-03-01 |
ES2070658B1 (es) | 1995-12-16 |
JP2628421B2 (ja) | 1997-07-09 |
FR2667944A1 (fr) | 1992-04-17 |
DE4122886A1 (de) | 1992-04-16 |
KR0167564B1 (ko) | 1999-03-30 |
BE1004994A5 (fr) | 1993-03-16 |
MX9101550A (es) | 1992-07-08 |
JPH04258765A (ja) | 1992-09-14 |
FR2667944B1 (fr) | 1993-07-30 |
KR920008491A (ko) | 1992-05-28 |
CN1036155C (zh) | 1997-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1036155C (zh) | 诊断和识别胸痛早期发作的诊断盒 | |
ES2339561T3 (es) | Procedimiento para la mejora de la recuperacion de troponina i y t. | |
Adams III et al. | Improved detection of cardiac confusion with cardiac troponin I | |
Adams 3rd et al. | Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I | |
Katus et al. | Non-invasive assessment of perioperative myocardial cell damage by circulating cardiac troponin T. | |
Lobetti et al. | Cardiac troponins in canine babesiosis | |
US7955811B2 (en) | Method for diagnosing and distinguishing stroke and diagnostic devices for use therein | |
JP2009532701A5 (zh) | ||
Voulgari et al. | Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. | |
CN108254563A (zh) | 检测cTnI的时间分辨荧光免疫层析试纸条、试剂盒及其制备方法 | |
Apple et al. | Cardiac troponin, CK-MB and myoglobin for the early detection of acute myocardial infarction and monitoring of reperfusion following thrombolytic therapy | |
Checchia et al. | Circulating cardiac troponin I levels in Kawasaki disease | |
Mair et al. | Clinical significance of cardiac contractile proteins for the diagnosis of myocardial injury | |
Larue et al. | Immunoradiometric assay of myosin heavy chain fragments in plasma for investigation of myocardial infarction | |
US7202042B2 (en) | Rapid evaluation of the ratio of biological molecules | |
Apple | The specificity of biochemical markers of cardiac damage: a problem solved | |
CN109696552A (zh) | 用于脑中风的发光elisa体外诊断试剂盒以及体外检测设备 | |
US20050136542A1 (en) | Stabilized liquid reference solutions | |
Peter et al. | The relevance of the detection of troponins to the forensic diagnosis of cardiac contusion | |
Durando et al. | Acute effects of short duration, maximal exercise on cardiac troponin I in healthy horses | |
Bhagat et al. | Cardiac troponin I should replace CKMB for the diagnosis of acute myocardial infarction | |
Yamahara et al. | Release kinetics and correlation with hemodynamic dysfunction of cardiac troponin T in coronary effluent from isolated rat hearts during reperfusion | |
Adamcova et al. | Troponin T levels in the cord blood of the healthy term neonates | |
Fagerberg et al. | Thyrotoxic atrial fibrillation: an underdiagnosed or overdiagnosed condition? | |
CN106716135A (zh) | 心力衰竭患者的检测方法、心脏疾病的识别方法、心力衰竭的检查试剂、心力衰竭的检查试剂盒、用于检测心力衰竭的装置及用于检测心力衰竭的程序 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |